Research article
Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer
-
* Corresponding author: Edgar Dahl edahl@ukaachen.de
- † Equal contributors
1 Molecular Oncology Group, Institute of Pathology, University Hospital of the RWTH Aachen, Pauwelsstrasse 30, D-52074 Aachen, Germany
2 Cancer Epigenetics Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Institute for Biomedical Research (ICO-IDIBELL), Av. Gran Via de L'Hospitalet 199-203, E-08907 Barcelona, Spain
3 Department of Internal Medicine IV (Haematology/Oncology), University Hospital of the RWTH Aachen, Pauwelsstrasse 30, 52074 D-Aachen, Germany
4 Department of Pathology, University of Erlangen, Krankenhausstrasse 12, D-91054 Erlangen, Germany
Breast Cancer Research 2009, 11:R34 doi:10.1186/bcr2319
Published: 15 June 2009Additional files
Additional data file 1:
A PDF file that demonstrates the specificity of the applied EDN3 antibody by use of competitive blocking peptide in immunohistochemistry.
Format: PDF Size: 1.3MB Download file
This file can be viewed with: Adobe Acrobat Reader
